TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03253614

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometry
Description: Extended high-frequency (EHF; 9-16 kHz) audiometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometry
Description: Extended high-frequency (EHF; 9-16 kHz) audiometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine biomarkers for renal tubular function
Description: Kidney Injury Molecule-1

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure
Description: Blood pressure right arm, measured With standard Methods 3 times
Study: NCT04170543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1, Dose 2, Dose 3, Dose 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg
Study: NCT02952300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neolix
Description: single rotation file

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wave one
Description: single reciprocation file
Study: NCT03668379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augment w/mHealth
Description: Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention.
Study: NCT02935647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprivan
Study: NCT03668379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Switch to CBT & mHealth
Description: Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switch to CBT & mHealth
Description: Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augment w/BAT & mHealth
Description: Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT.
Study: NCT02787746

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil
Description: Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
Study: NCT03940365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Life tocometer device
Description: The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
Study: NCT02399150

Intervention type: OTHER
Intervention: No intervention as observational study
Study: NCT01838369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-505
Study: NCT01350882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera
Description: MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
Study: NCT02370420

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: Autologous Platelet-Rich Plasma will be applied by a intra-articular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Autologous Platelet-Rich Plasma will be applied by a intra-articular injections

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation exercises
Description: Patients would been shown rehabilitation exercises, to perform them at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation exercises
Description: Patients would been shown rehabilitation exercises, to perform them at home
Study: NCT02650180

Intervention type: DEVICE
Group type: OTHER
Intervention: Soberlink Cellular Device
Description: Alcohol Breath Analyzer
Study: NCT03789240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
Study: NCT02928575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
Study: NCT01966926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weighing frequency instructions and tips
Description: Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weighing frequency instructions and tips
Description: Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
Study: NCT01932216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Gallbladder removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Gallbladder removal
Study: NCT03246867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic stretching group
Description: In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching group
Description: In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
Study: NCT03193606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nano silver fluoride solution
Description: prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
Study: NCT00808288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: oral, inhaled, dry powder, 600ug, OD
Study: NCT02806700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter Diabetes Intervention
Description: This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
Study: NCT04300049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Infusion
Description: Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Study participants will receive saline infusion for 12 hours.
Study: NCT00808288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF - 00610355
Description: oral, inhaled, dry powder, 300ug, OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF- 00610355
Description: oral, inhaled, dry powder, 100ug, OD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, inhaled, dry powder, placebo, OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: salmeterol, 50ug, BID
Study: NCT04243005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supramarginal resection
Description: Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
Study: NCT02150889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running Program
Description: 16 week supervised running program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program
Description: once weekly supervised yoga
Study: NCT02111252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850
Description: TAK-850 injection
Study: NCT02773043

Intervention type: DEVICE
Group type: OTHER
Intervention: CZT SPECT camera
Study: NCT00774033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous epidermal cells harvesting kits
Description: autologous epidermal cells harvesting kits used for the treatment of acute burn

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic skin grafts
Description: classic skin grafts used for the treatment of acute burn
Study: NCT01454934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Description: * Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only).
Study: NCT03307148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Administered orally on D1-15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous Infusion on D1,8 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
Study: NCT03804554

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT04286438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) Infusion
Description: Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452.
Study: NCT04726631

Intervention type: DRUG
Group type: OTHER
Intervention: Basal insulin analogue
Description: Analogue insulin is a sub-group of human insulin

Intervention type: DRUG
Group type: OTHER
Intervention: rapid acting insulin
Description: Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.

Intervention type: DRUG
Group type: OTHER
Intervention: Neutral Protamine Hagedorn
Description: is an intermediate-acting insulin

Intervention type: DRUG
Group type: OTHER
Intervention: regular insulin
Description: is a type of short-acting insulin.
Study: NCT01752608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCBT Mood
Description: A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
Study: NCT04228068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Program
Description: PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain self management
Description: In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
Study: NCT02284880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: MF - Marketed formulation
Study: NCT02331186

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: bariatric surgery for obese women
Study: NCT03741582

Intervention type: OTHER
Intervention: TransMiCable
Description: TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices.
Study: NCT02284880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: MF - Marketed formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: TBM - to-be-marketed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: TBM - to-be-marketed
Study: NCT02264886

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-guided stereotactive body radiation therapy
Study: NCT01019746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol administration
Study: NCT02599298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep-Study Guided Multidisciplinary Therapy
Study: NCT05329012

Intervention type: DEVICE
Intervention: DUL- Distal Ulna Locking PLate (I.T.S)
Description: The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
Study: NCT01165424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.
Study: NCT00887965

Intervention type: DRUG
Group type: OTHER
Intervention: Previous denosumab
Description: Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
Study: NCT02987946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPD Device delivered by Converis
Description: After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fraxiparine
Description: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fraxiparine
Description: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
Study: NCT00776971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drink
Description: 500mL as a preload drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened soft drink
Description: 500mL as a preload drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-skimmed milk
Description: 500mL as a preload drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 500mL as a preload drink
Study: NCT01350882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum : sodium chloride, sodium citrate
Description: Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
Study: NCT00392691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan
Description: 185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients \> 80kg) for imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 250 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: * Dose level 1: 100 mg/m2~* Dose level 2: 140 mg/m2~* Dose level 3: 170 mg/m2~* Dose level 4: 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate / G-CSF
Description: on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell harvesting and transplantation
Description: Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils \> 0.5x109/l for at least 2 consecutive days.
Study: NCT04186442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Active Comparator